Target Price | $517.50 |
Price | $471.12 |
Potential | 9.84% |
Number of Estimates | 28 |
28 Analysts have issued a price target Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals target price is $517.50. This is 9.84% higher than the current stock price. The highest price target is $600.00 27.36% , the lowest is $325.00 31.02% . | |
A rating was issued by 37 analysts: 21 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2025 of 9.84% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
30 Analysts have issued a sales forecast Vertex Pharmaceuticals 2024 . The average Vertex Pharmaceuticals sales estimate is $10.8b . This is 4.27% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.9b 5.73% , the lowest is $10.6b 3.00% .
This results in the following potential growth metrics:
2023 | $9.8b | 12.47% |
---|---|---|
2024 | $10.8b | 9.40% |
2025 | $11.7b | 8.72% |
2026 | $12.9b | 10.00% |
2027 | $14.1b | 9.46% |
2028 | $15.3b | 8.76% |
8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2024. The average Vertex Pharmaceuticals EBITDA estimate is $821m . This is 550.26% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.0b 666.64% , the lowest is $661m 462.59% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $4.5b | 5.44% |
---|---|---|
2024 | $821m | 81.58% |
2025 | $5.7b | 593.72% |
2026 | $6.3b | 9.84% |
2027 | $7.1b | 13.02% |
2028 | $7.8b | 9.62% |
2023 | 45.32% | 6.25% |
---|---|---|
2024 | 7.63% | 83.16% |
2025 | 48.68% | 538.01% |
2026 | 48.61% | 0.14% |
2027 | 50.19% | 3.25% |
2028 | 50.59% | 0.80% |
17 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Vertex Pharmaceuticals net profit estimate is $-679m . This is 29.60% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $-459m 12.31% , the lowest is $-1.4b 160.74% .
This results in the following potential growth metrics and future Net Margins:
2023 | $3.6b | 8.35% |
---|---|---|
2024 | $-679m | 118.94% |
2025 | $4.3b | 737.77% |
2026 | $4.9b | 13.86% |
2027 | $5.6b | 13.77% |
2028 | $6.3b | 12.58% |
2023 | 36.43% | 3.67% |
---|---|---|
2024 | -6.31% | 117.32% |
2025 | 36.99% | 686.21% |
2026 | 38.29% | 3.51% |
2027 | 39.80% | 3.94% |
2028 | 41.20% | 3.52% |
17 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-2.63 . This is 29.56% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-1.78 12.32% , the lowest is $-5.29 160.59% .
This results in the following potential growth metrics and future valuations:
2023 | $13.89 | 8.35% |
---|---|---|
2024 | $-2.63 | 118.93% |
2025 | $16.78 | 738.02% |
2026 | $19.10 | 13.83% |
2027 | $21.73 | 13.77% |
2028 | $24.47 | 12.61% |
Current | -232.56 | 946.90% |
---|---|---|
2024 | -179.08 | 23.00% |
2025 | 28.08 | 115.68% |
2026 | 24.66 | 12.18% |
2027 | 21.68 | 12.08% |
2028 | 19.25 | 11.21% |
Based on analysts' sales estimates for 2024, the Vertex Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 10.85 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 11.30 .
This results in the following potential growth metrics and future valuations:
Current | 11.31 | 30.30% |
---|---|---|
2024 | 10.85 | 4.11% |
2025 | 9.98 | 8.02% |
2026 | 9.07 | 9.09% |
2027 | 8.28 | 8.64% |
2028 | 7.62 | 8.05% |
Current | 11.78 | 20.20% |
---|---|---|
2024 | 11.30 | 4.10% |
2025 | 10.39 | 8.02% |
2026 | 9.45 | 9.09% |
2027 | 8.63 | 8.64% |
2028 | 7.93 | 8.05% |
Vertex Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.